Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination - Harbeck, N; Kates, RE; Schmitt, M (J Clin Oncol, 2002)